HER2 mutations in advanced non-small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study is looking at how common HER2 gene changes are in people with advanced non-small cell lung cancer (NSCLC) and how these changes affect treatment. By joining, you help researchers learn more about personalized care for this type of lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with non-small cell lung cancer (NSCLC) between September 2024 and September 2025.
- Your cancer is at an advanced stage (IIIC or IV) that cannot be removed with surgery or treated with chemo-radiation.
- You are enrolled in a related study called the ATLAS project.
- If you have a HER2 mutation, you may be asked to provide a tissue sample for further analysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This trial tests combining two targeted therapies (an EGFR inhibitor and a HER2-targeted drug) for advanced lung cancer that has both an EGFR mutation and a HER2 change. The goal is to see if this combination works better than current treatments.
This study looks at a test called HER2 IHC (a way to check for a protein called HER2 on tumor cells) in people with certain cancers: non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), gynecological cancers (cervical, endometrial, ovarian), and urothelial cancer (UC). It aims to see how well the test works in different patients. You may join if you have enough stored tumor tissue from a biopsy or surgery done within the past 5 years.
This trial tests a combination of two study drugs for a type of lung cancer that has a specific genetic change (HER2). Doctors want to see if this combination can help treat the cancer when it is advanced.
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.